AEterna Zentaris (AEZS) Trading Up 16.4%
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)’s share price was up 16.4% during mid-day trading on Thursday . The company traded as high as $3.07 and last traded at $2.41. Approximately 16,259,300 shares changed hands during mid-day trading, an increase of 851% from the average daily volume of 1,709,936 shares. The stock had previously closed at $2.07.
A number of equities analysts recently issued reports on AEZS shares. Maxim Group set a $4.00 price target on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Tuesday, November 28th. HC Wainwright set a $3.00 price target on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Finally, Zacks Investment Research lowered AEterna Zentaris from a “buy” rating to a “hold” rating in a research report on Monday, January 15th.
The company has a market capitalization of $37.13, a PE ratio of -1.26 and a beta of 0.87.
A hedge fund recently raised its stake in AEterna Zentaris stock. JPMorgan Chase & Co. boosted its holdings in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 56,800 shares of the biopharmaceutical company’s stock after buying an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent quarter. 2.01% of the stock is currently owned by institutional investors.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.